Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 13, 2023

Rhea-AI Summary

Medpace Holdings, Inc. (NASDAQ: MEDP) will release its fourth quarter and fiscal year 2022 financial results on February 13, 2023, after market close. A conference call is scheduled for February 14, 2023, at 9:00 a.m. ET to discuss these results. Participants can register in advance through the provided link. The call will also be accessible via webcast on Medpace's investor website, with a replay available after the event. Medpace is a global clinical contract research organization offering comprehensive services across various therapeutic areas.

CINCINNATI--(BUSINESS WIRE)-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2022 financial results after the market close on Monday, February 13, 2023. The Company will host a conference call the following morning, Tuesday, February 14, 2023, at 9:00 a.m. ET to discuss these results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,000 people across 40 countries as of September 30, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005863/en/

Investor Contact:

Lauren Morris

513.579.9911 x11994

l.morris@medpace.com

Media Contact:

Julie Hopkins

513.579.9911 x12627

j.hopkins@medpace.com

Source: Medpace Holdings, Inc.

FAQ

When will Medpace report its fourth quarter and fiscal year 2022 earnings?

Medpace will report its financial results on February 13, 2023.

What is the date and time of Medpace's earnings call?

The earnings call is scheduled for February 14, 2023, at 9:00 a.m. ET.

How can I participate in Medpace's earnings call?

To participate, register in advance through the link provided in the press release.

Will there be a replay of Medpace's earnings call?

Yes, a replay will be available on Medpace's investor website approximately one hour after the call.

What kind of organization is Medpace?

Medpace is a global, full-service clinical contract research organization providing Phase I-IV clinical development services.